• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Malaysia·Consumer Cyclical·5247.KL
Share

Karex Berhad Stocks

MYR 0.47Last Updated 21.09.2026

Issuer Rating

3/7
Performance

Average

Risk

Considerable

Recommendation

Sell

Market Cap

MYR 121.47M

MYR 0.47
Key Takeaways

Risk factor

Very poor trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Greatly overvalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Established in 1988 and headquartered in Port Klang, Malaysia, Karex Berhad operates as an investment holding company primarily focused on the manufacturing and distribution of condoms. The company offers a comprehensive range of products, including personal lubricants, medical probe covers, and Foley balloon catheters utilized for transurethral urinary bladder drainage, alongside gloves. Its product portfolio has expanded to also include hand sanitizers and pre-vulcanised latex items, in addition to a wholesale service for various healthcare goods. Karex Berhad maintains a global presence, conducting business across Africa, Asia, the Americas, and Europe, serving a diverse client base that encompasses brand owners, governmental bodies, non-governmental organizations, and individual retail purchasers.

Company Valuation

Greatly overvalued
1/7

Based on key historical and expected multiples, the stock is greatly overvalued relative to its peers. Specifically, the stock is 'expensive' on P/E, overvalued on EV/EBI

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Somewhat favourable
5/7

The average target price of 5247.KL is 0.54 and suggests 16.1% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to i

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

23.09.2026 10:56

FT: The U.S. Backed Chelsea's Former Co-Owner in His Battle with Carlyle Over Lukoil Assets

23.09.2026 10:45

Hawkish Easing: Why BofA Is Betting on Forward Contracts in Kazakhstan

23.09.2026 10:37

Top Stories This Morning: OpenAI and Anthropic Have Made Their AI Models More Affordable; Qualcomm Unveiled a New Chip

23.09.2026 09:00

Apple is developing a new type of device, according to Bloomberg. What is known about the gadget?

23.09.2026 07:30

In the U.S., a second IPO has been canceled in less than a week. Why is this a cause for concern?

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026